Related Experiment Video

Updated: Jan 2, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations

Yolanda Jerez1,2, Ivan Márquez-Rodas1,2, Inmaculada Aparicio1

  • 1Medical Oncology Service, Departamento de Medicina, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Drugs
|December 12, 2019
PubMed

Insights

Poly-(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib improve progression-free survival in metastatic breast cancer (BC) with BRCA mutations. Future research explores PARP inhibitors in combination therapies and earlier BC stages.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Metastatic breast cancer (BC) with germline BRCA mutations has limited treatment options.
  • Poly-(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib offer improved progression-free survival over chemotherapy.
  • PARP inhibitors represent a significant advancement in targeted therapy for specific BC subtypes.

Purpose of the Study:

  • To review the mechanism of action of PARP inhibitors (PARPi) in breast cancer.
  • To contextualize the clinical trial results of approved PARPi (olaparib, talazoparib).
  • To discuss the future directions and potential combinations for PARPi in BC treatment.

Main Methods:

  • Literature review of pivotal clinical trials evaluating PARP inhibitors in breast cancer.
  • Analysis of drug mechanisms and clinical outcomes.
  • Discussion of emerging treatment strategies and genetic counseling implications.

Main Results:

  • Olaparib and talazoparib demonstrate superior progression-free survival compared to chemotherapy in metastatic BC with BRCA mutations.
  • PARPi are being investigated in various clinical trial settings, including earlier disease stages and combination therapies.
  • The efficacy of PARPi highlights the importance of genetic testing in BC patient selection.

Conclusions:

  • PARP inhibitors are established therapies for BRCA-mutated metastatic breast cancer.
  • Ongoing research focuses on expanding the role of PARPi through novel combinations and earlier treatment interventions.
  • The integration of PARPi necessitates updated genetic counseling protocols for breast cancer patients.

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

29.6K
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

5.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.9K